Gen Eng News: More CO Action!

If memory serves me correctly I have waxed on in the past about my affinity for Genetic Engineering News and often highlighted the journal when a Colorado company ended up in print there. Well the love story continues with the 15 November issue where Carol Potera composed a three-page treatise on the Colorado Science + Technology Park @ Fitzsimons and beyond.

A few companies highlighted include 1) MBC Pharma who is focused upon bone disease such as osteoporosis and cancer metastases, patients who die from breast, prostate or lung cancer have bone metastases and, presentation with bone metastases is correlated with shorter survival 2) MycoLogics, a company near and dear to my heart that is among other pursuits focused upon developing prophylactic and therapeutic approaches to Leishmaniasis, a disease where 350 million people in developing countries are at risk. 3) Caveo Therapeutics who is working on the discovery and development of biopharmaceuticals to treat and cure hematalogic conditions by inhibiting certain families of tyrosine kinases 4) ARCA Discovery who is developing genetically targeted therapies for heart failure and other cardiovascular disease, an NDA for bucindolol is expected to be filed shortly, and finally 5) Lohocla Research is a discovery and development company specializing in addiction, neurological disorders and related biomarkers for companion diagnostics.

You can read the article (here).

If you enjoyed this post get free email updates (here).

MBC Pharma: Managing Toxicity Risk

MBC Pharma, Inc. is working to commercialize pharmaceutical technology invented by the late Prof. Marat Karpeisky and Professor H.B.F. Dixon. They were joined by H. Lee Sturgeon (Cortech co-founder) to form the company. MBC intends to establish the therapeutic potential of its vitamin B6-bisphosphonate family of compounds as new therapies for osteoporosis and complications arising from metastatic bone disease. The oncology products are being developed to treat metastatic bone disease associated with the three most prevalent cancers (breast, prostate and lung) plus multiple myeloma. The lead structures are unique in that they are new chemical entities, proprietary to the company, yet are constructed from established and proven drugs, therefore managing the risk of clinical stage failure due to toxicity or lack of efficacy. In addition, MBC will expand its patented chemotherapy-bisphosphonate conjugates as therapeutic modalities for direct treatment of metastatic tumors and, pursue applications of its intellectual property in new disease areas. The Company has raised approximately $1.2 million to date through grants and private funding and will leverage those funds with SBIR and STTR grants to achieve early stage, preclinical development goals.